Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
NCT03596645Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2018
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 3 trial of golimumab in ulcerative colitis (UC), sponsored by Janssen Pharmaceutical. Started Oct 2018; status: active, not recruiting.
02
Drugs
golimumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03596645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03596645.